Has cabozantinib been included in the scope of medical insurance reimbursement?

Cabozantinib, as a highly effective anti-cancer drug, is relatively expensive. Therefore, whether it is included in the scope of medical insurance reimbursement has become a concern for many patients. So far, cabozantinib has not been fully included in the national medical insurance directory in China, which means that patients may need to bear higher drug costs when using the drug. However, cabozantinib may be reimbursed to a certain extent through different channels in some regions and specific medical institutions. The specific reimbursement policy needs to be determined according to local medical insurance policies and relevant regulations of medical institutions.

In some developed countries and regions, such as the United States and the European Union, cabozantinib has been reimbursed by medical insurance as an effective drug for the treatment of advanced renal cancer, advanced hepatocellular carcinoma and dedifferentiated thyroid cancer. However, in China, due to high drug prices and restrictions in the medical insurance catalog, the use of cabozantinib is still limited by certain financial burdens. In order to cope with this problem, some medical institutions and patients may obtain drug treatment by purchasing it at their own expense or seeking other funding channels.

In addition, the drug price of cabozantinib in China is usually relatively expensive, which is one of the main reasons why it is not included in medical insurance. The price of cabozantinib can vary depending on the drug's specific strength and manufacturer, but is generally on the higher end of the spectrum. This does bring a certain burden to some patients with limited financial conditions.

Nonetheless, with the gradual advancement of domestic medical insurance policies for anti-cancer drugs, some drugs are expected to enter the scope of medical insurance reimbursement. Therefore, patients need to communicate in detail with doctors and hospital pharmacies during treatment to understand whether they can be reimbursed through medical insurance or whether there are other financial assistance channels that can reduce the cost burden.

Reference:https://en.wikipedia.org/wiki/Cabozantinib